Freedom to Live Life Fully

KORU™ MEDICAL SYSTEMS

A Global Leader in Large-Volume Subcutaneous Drug Delivery

Nasdaq: KRMD

Corporate Overview

November 2025

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements.

Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as "targets", "guidance", "expected", "plan", "drivers", "milestones", "opportunity", "believe" and "will", and include without limitation expected clearance and launch dates for 510(k) submissions and new products, anticipated oncology market entry, and 2025 full year financial guidance (revenues, gross margin and cash usage and balance). Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with success of pharma collaborations, SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, tariffs and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of November 12, 2025. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Revenues: All references to revenue(s) in this presentation refer to net revenues.

Our Company

We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic

KORU's Freedom Infusion System is a **global leader in large-volume (>10mL) drug delivery**

Capitalizing on the ongoing shift from intravenous (IV) hospital settings to **subcutaneous (SC) therapy in the home and in infusion clinics**

Our subcutaneous Freedom Infusion System is, today, primarily used by **45,000 chronic, recurring** subcutaneous immunoglobulin (SCIg) drug therapy patients

Expanding our market beyond SCIg via 9 current collaborations with pharmaceutical companies to bring **new drug therapies** onto our label

Leveraging a low cost go-to-market model by serving pharmaceutical companies, specialty pharmacies, home care networks, and distributors

Our Company

KORU at a Glance

FREEDOM INTEGRATED INFUSION SYSTEM

70+ Global Patents

DRUG CLEARANCES / REGISTRATIONS

8 Drugs / 36 Countries

First Subcutaneous Drug Clearance 2010

FY 2025 REVENUE GUIDANCE

$40.5-$41M[1]; ~21% y/y growth

75%+ Recurring

$10M UNDRAWN DEBT FACILITY IN PLACE

$8.5M Cash Balance[1]

3Q25 Cash Generation of $0.4M

HEADQUARTERS/MANUFACTURING

Mahwah, NJ



FY2024 REVENUES

$33.6M

- Domestic Core
- International Core
- Pharma Services & Clinical Trials

Pharma Services and Clinical Trials

Revenue from pre-commercial pharmaceutical drug collaborations utilizing Freedom Infusion System

Clinical Trial Supplies

Non-Recurring Engineering Services

Domestic & International Core

Freedom Infusion System sales for on-label commercialized drugs

~10% Other

~90% Ig Drugs

Pharmaceutical drug collaborations move to Core business following 510(k) clearance for use of the drug with the KORU Freedom Infusion System

1. As of Q3 Earnings Press Release published on November 12, 2025

Our Company

KORU's Freedom Infusion System

Mechanical Pumps
~20% of revenues

Freedom60® INFUSION SYSTEM

FreedomEDGE® INFUSION SYSTEM

Customizable Consumables
~80% of revenues



Precision™ FLOW RATE TUBING



High-Flo™ SUBQ NEEDLE SET

Simple, Easy-to-use, Reusable mechanical pump

8 On-label SC drugs[1]

2M+ annual infusions, 45k+ recurring chronic patients (ages 6-93)

97% Patient adherence rate[2]

Customizable platform for use with large-volume SC drugs

Registered in 36 countries

1. Includes CSL Hizentra, Octapharma Cutaquig and Gammanorm, Takeda Cuvitru, Hyqvia and Gammagard Liquid, Grifols Xembify, and Apellis Empaveli 2. Rutland B, Bosshard J, Southworth C. Enhancing Drug Adherence and Patient Outcomes: The Role of SCIG Pump Selection in Subcutaneous Immunoglobulin Therapy for Primary Immunodeficiency Disease. Poster presented at: National Home Infusion Association Annual Conference; March 23-27, 2024; Austin TX.

KORU's Opportunity

The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity

Global Total Addressable Market for Large-Volume Subcutaneous >10ml Infusion

SCIg Opportunity

$450M[1]

Total global addressable market with <20% SCIg penetration : 8 launched SCIg drugs

Non-SCIg Opportunity

95+

New Drugs in Development >10 mL[2]

KORU'S Strategic Growth Pillars

1. **Protect and Grow our Core Domestic Business**
2. **Expand Internationally**
3. **Enable More Drugs, Reach More Patients**

1. TAM based on patient population and expected treatment frequency; third party data on file 2. Third party data on file

KORU's Opportunity

Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities



1

- On label w/KORU Freedom Infusion System
- On label w/on-body infusion device
- Drugs administered with manual push syringe
- Drugs administered with e-pump system
- Pre-Commercial[2]
- In Clinical Development

7 LVSC drugs have launched between 2010-2019, 6 of which were in the Ig drug class and approved with the KORU Freedom Infusion System

Between 2020-2025, 11 drugs have launched, and the LVSC market has diversified, primarily in oncology

There are 15+ new drugs in the clinical pipeline as pharma companies are increasingly adding SC formulations

1. Third Party Data on File 2. Timing based on pharma company estimates

KORU's Opportunity

KORU is Well Positioned to Capitalize on the Expanding SC Market Opportunity

Market Proven Freedom Infusion System

- 15+ years on market; 2.2M+ infusions annually
- Underlying US SCIg market growing ~8-10%[1]
- Fully reimbursed system with 97% adherence rate and 8 on-label SC drugs
- Enables transition from hospital to home

Efficient, Scalable Go-to-Market Strategy

- Drug Rx volume driven by pharma companies
- US → Specialty pharmacies and homecare networks
- OUS → Exclusive distributors

Razor-Razor Blade Model; 75%+ Recurring Revenue

- Razor = 3+ years lifespan on pump
- Razor Blade = needles/tube sets drive recurring revenue
- Consumables compatible with mechanical and e-pumps

$2.3B TAM with Ig and New Drug Indications

- Fully customizable system to accommodate almost any large volume SC drug
- Expanding beyond $450M global Ig market with new drug therapy areas adding additional $1.8B in TAM[2]
- Opportunity in oncology infusion clinics targeting 7 commercially launched drugs using manual syringe push

1. KORU Medical Estimates and Third-Party Data on File 2. TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk

KORU's Opportunity

$2.3B[1] Total Addressable Market Opportunity with Growing SCIg Market and Expansion to New Drug Therapies

8 SC Drugs Currently on KORU's Freedom Infusion System (primarily Ig)

cutaquig®
gammanorm®
Cuvitru
Hizentra®
EMPAVELI™
HyQvia
GAMMAGARD LIQUID
Xembify® (immune globulin subcutaneous human-klhw) 20%

+ an Additional 7 Ig Device/Indication Collaborations

$450M Ig TAM[1]
Growing 8-10% /year

11 Active Opportunities to add New Drugs/Indications to KORU's Freedom Infusion System

- Vancomycin
- Deferoxamine
- 1 in Oncology
- 2 in Nephrology
- 1 in Rare Disease
- 1 in Endocrinology
- 1 in Respiratory
- 2 in Hematology
- Forcast Ortho

$1.8B TAM[1]

KORU's Future Opportunities in Clinical-Stage and Commercialized Large-Volume SC Drugs

Other	2
Central Nervous	5
Immunology	5
Oncology	6

Opportunity for Significant TAM Expansion

1.TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk

KORU's Opportunity

Global Ig Business Drives Annual Recurring Revenue Base

Global Patient Base

45k+ Patients using the KORU Freedom Infusion System today, representing 2M+ annual recurring infusions

Current 510(k) Clearances

8 SCIg drugs from 5 major pharmaceutical manufacturers cleared for use on the KORU Freedom Infusion System



Chronic Disease with Weekly Recurring Treatments

Chronic disease (PIDD, CIDP, etc.) patients receive SCIg doses 1-2x per week for the remainder of their lives

7 New Ig Pharmaceutical Collaborations

New indications and devices give us opportunity to expand our market share and geographic reach

$450M TAM[1] — Global Ig market totals $450M TAM; 20% penetrated by SC (vs 80% IV)

8-10% Market growth[2] — SCIg Market is growing 8-10% year globally; new patients begin treatment protocol annually

≈$750-$1,000 Annual revenue per patient — Recurring revenue generated by each Ig patient on the KORU Freedom Infusion System; based on 1x pump sales + weekly consumables

1. TAM based on patient population, expected treatment frequency. Not adjusted for clinical risk 2. KORU Medical Estimates and Third-Party Data on File

KORU's Opportunity

75% Recurring Revenues from a Growing Patient/Infusion Base



Strong Recurring Base that is Expected to Grow

75% of KORU's revenue is recurring
Removing initial 1x sale of pumps and PST service revenue

Recurring SCIg patient base
~45k+ KORU chronic SCIg patients
~2M+ KORU annual infusions

KORU outperforming market growth[1]
8-10% US SCIg Growth
Outperformance driven by share gains and new market entries

1. Third party data & KORU Medical estimates

Ig Pipeline

Core Ig Business Continues to be Fueled with New Opportunities with Pharma Customers

7 Collaborations/Opportunities w/ 4 Ig Manufacturers | **2 Commercial Opportunities by 2026** | **$450M Total Ig TAM[2]**

New Ig Indications and Devices with 7 Pharma Collaborations Drive Share Gains and Geographic Expansion

Asset	Drug Status	Expected KRMD Clearance[1]	Details	Recent Update
Ig Device- Japan Launch	Launched	✓ Phase I-'25 Phase II- '26	KRMD flow controller for use with launched drug	
Ig Device (Pump)	Launched	2026	KRMD next gen Ig pump	
Ig Device (Pump)	Launched; New Device Pending	2027	KRMD next gen. Ig pump	2026 → 2027
Ig Device (Pump)	Launched; New Device Pending	2027	KRMD next gen. Ig pump	2026 → 2027
Ig Drug/Device	Phase III	2027/28	New drug launch using KRMD device	
Ig Drug/Device	Phase II/III	2027/28	New drug launch using KRMD device	
Ig Device (Pump)	Launched; New Device Pending	2028	KRMD next gen. Ig pump	Added to pipeline

Update since prior quarter

1. Clearance and launch dates are based on most recent estimation and are subject to change 2. TAM and annual infusions are estimates of total patient population and dosing schedule,, not adjusted for clinical risk

Non Ig Pipeline

4 New Drug Additions planned on KORU Freedom Infusion System by 2026

9 Collaborations/ 11 Opportunities | **4 Commercial Opportunities by 2026** | **$1.8B Total TAM[2]**

KRMD Pursuing Drug Label Independently

	Asset	Drug Trial Phase	Next Step	Expected KRMD Clearance[1]	Est. Global Total Annual Infusions[2]	Recent Update
Launched or late-stage opportunities	Vancomycin	Launched	KRMD 510(k) Submission	2026	~900k	
	Deferoxamine	Launched	KRMD 510(k) Submission	2026	~200k	

KRMD Pursuing Drug Label through Pharmaceutical Collaborations

	Asset	Drug Trial Phase	Next Step	Expected KRMD Clearance[1]	Est. Global Total Annual Infusions[2]	Recent Update
✓	**Empaveli C3G/IC-MPGN**	**Launched**	Commercialize	Complete	~100k	
Launched or late-stage opportunities	**Rare Disease Biologic**	**Launched**	KRMD 510(k) Clearance	2026	~270k	Under FDA Review
	Oncology Drug	**Launched**	KRMD 510(k) Submission	2026	~1,100k	
	Empaveli FSGS	**Phase III**	Complete Phase III	2027	~25k	New Indication
	KIRA (PNH)	**Phase III**	Entry to Phase III	2027/28	TBD	
	Endocrinology Drug	**Phase III**	Complete Phase III	2028	~1,000k	
	Respiratory Drug	Phase II	Complete Phase II	2028/29	~1,165k	
	KIRA (IgAN)	Phase II	Complete Phase II	2029/30	TBD	
	KIRA (C3G)	Phase II	Complete Phase II	2029/30	TBD	
	ForCast Orthopedics	Phase I	Entry to Phase I	2030	~140K	Deal Signed

Update since prior quarter

1. Clearance and launch dates are based on most recent estimation and are subject to change 2. TAM and annual infusions are estimates of total patient population and dosing schedule,, not adjusted for clinical risk

Financials & Outlook

Financial Highlights



2024 Revenue

$33.6M; 18% y/y growth, guiding 2025 revenue of $40.5-$41.0M[1]

14.5% Revenue CAGR

More than tripled size of Company in 10 years

Cash Flow Positive in Q3 2025

YTD25 cash burn of $1.1M, a 60% improvement from YTD24

Cash & Cash Equivalents[1]

$8.5M cash on hand, $10M undrawn debt facility in place

YTD 2025 Financial Highlights

	YTD 2025	YTD 2024	Y/Y Δ
Revenue	$30.2M	$24.8	22% Growth
Gross Margin	62.1%	63.6%	150bps Decrease
OpEx	$21.2M	$20.6M	3% Increase
Net Loss	($2.2M)	($4.5M)	51% Improvement
Adj. EBITDA*	$0.12M	($1.7M)	109% Improvement
Adj. EPS*	$0.00	($0.05)	50% Improvement
Cash Usage	($1.1M)	($2.7M)	60% Decrease

KORU

* Refer to Appendix Slide

1. As of Q3 Earnings Press Release published on November 12, 2025

Financial Profile



1. As of Q3 Earnings Press Release published on November 12, 2025 2. Per most recent strategic plan

Outlook

Sustained Pathway to +20% Growth



Key Growth Drivers

Sustained share of SCIg market growth and share gains
8-10% annual growth

New product launches & innovation
2nd generation consumables, new PFS pump, and flow controller

Entry into new SCIg markets & expansion of established markets
Western EU, Japan, Canada

New drugs on label
Includes current pipeline

Our Company

Strong Foundation; Experienced Pharma and MedTech Leadership Team Focused on Execution

- 44,000 sq. ft. Facility:
  - Class 8 cleanrooms
  - Controlled manufacturing environment
  - R&D laboratory space
  - In-house distribution center
- ISO 13485/MDSAP/EU MDR Certified Quality Management Systems
- Successful Notified Body and Pharmaceutical customer audit outcomes

LINDA THARBY
Chief Executive Officer & President

TOM ADAMS
Chief Financial Officer

ADAM KALBERMATTEN
Chief Commercial Officer

CHRIS PAZDAN
Chief Operating Officer

BRENT RUTLAND
Vice President of Medical Affairs

BRIAN HERTZOG
Vice President of Biopharma Business Development

Baxter BD Pfizer Roche

Nemera McKESSON La Jolla Pharmaceutical

TERUMO ZEBRASCI Combination Product Experts

Outlook

Execution Milestones on Path to Accelerated Revenue Growth

2025 Financial Targets and Guidance

- **Revenue $40.5-$41.0M; 20-22% growth** ✓
- **Positive cash flow from operations for FY2025, Positive in 3Q25** ✓
- **Adj. EBITDA growth, higher gross profit, increased operating leverage** ✓

Enable More Drugs, Reach More Patients

- **4 new pharmaceutical collaborations YTD** ✓
- 510(k) submission Deferoxamine (1H 2026)
- 510(k) submission Vancomycin (Q1 2026)
- **510(k) submitted Rare Disease Drug for infusion clinic (2Q 2025)** ✓
- 510(k) submission Oncology Drug for infusion clinic (2025)

Expand Internationally

- **Japan Commercial Sales Q3 2025** ✓
- **Phase 1 flow controller launched Q2 2025** ✓
- 510(k) submission Phase 2 flow controller (2026)
- **Further top-10 market penetration** ✓

Protect and Grow our Core Domestic Business

- **Outpacing sustained ~8-10% SCIg drug market growth** ✓
- 510(k) submission new consumables (2H 2026)
- 510(k) submission next gen. pump (2026)



KORU

Outlook

Strategically Positioned for Accelerated Growth

1. **Macro tailwinds** driving **adoption of subcutaneous therapy**; >95 large-volume (>10mL) SC drugs in development by major Pharma companies in multiple indications

2. **Strong underlying SCIg market**; gaining greater market share domestically and **expanding in top-ten global markets**

3. Above-market growth in Core business with **~75% recurring revenues**

4. **11 non-SCIg new drug opportunities in pipeline;** oncology and rare disease indications will **expand our presence outside of the home and into infusion clinics**

5. **Raising 2025 revenue guidance,** and positioned for accelerated revenue growth

KORU

KORU™
MEDICAL SYSTEMS

Appendix

Growth Opportunities

US SCIg Market Remains Strong with 9%+ Forecasted Growth through 2029

Total US Ig Market, Historical and Forecasted[1]



Drivers of Future SCIg Growth

Increasing US SCIg penetration
Market driven by new PID patients and increasing SID population

Pharma investments in SCIg
Driving market shift to subcutaneous therapy with prefill conversions and expanded indications

KORU growing SCIg leadership position
Driven by account wins and innovation pipeline resulting in double-digit end user specialty pharmacy demand growth

1. Third Party Proprietary Data Source

Growth Opportunities

International Expansion Fueling Growth with Opportunity for Further Market Share Gains

Growing KORU Market Share with Significant Room for Additional Penetration



Opportunity for Accelerated International Growth

Large and underpenetrated
KORU has grown market share from ~10% to ~15-20% since 2024; significant room for growth remains

Prefill market conversion driving increased use of KORU Freedom mechanical pumps
Vial to prefilled conversion in multiple markets across the EU

Growth opportunities
Further expansion in top-10 markets

Continued opportunity for cross promotion
KORU needle sets used with electronic pumps

1. Third party data & KORU Medical estimates

Oncology Opportunity

Strategic Oncology Infusion Market Entry Initiative Progressing to Plan

Currently 7 Subcutaneous Oncology Drugs Available on the Market Using Syringe Manual Push

DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use | 1,800mg/30,000units

TECENTRIQ Hybreza™ atezolizumab/hyaluronidase-tqjs SUBCUTANEOUS INJECTION 1875 mg/30,000 units

KEYTRUDA Qlex™ pembrolizumab + berahyaluronidase alfa-pmph Subcutaneous Injection | 165 mg + 2,000 units/mL

Herceptin HYLECTA™ trastuzumab and hyaluronidase-oysk INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units

PHESGO® pertuzumab/trastuzumab/hyaluronidase-zzxf SUBCUTANEOUS INJECTION | 1,200 mg/600 mg/30,000 units / 600 mg/600 mg/20,000 units

RituxanHYCELA® rituximab/hyaluronidase human subcutaneous injection | 1,400 mg/23,400 Units | 1,600 mg/26,800 Units

OPDIVO Qvantig™ nivolumab + hyaluronidase-nvhy SUBCUTANEOUS INJECTION | 120 mg + 2,000 units/mL

~$138M
2030[1] TAM

~$60M
Oncology Infusion Pump & Consumables
2025[1] TAM

Successful US Pilot Study Validated Value Proposition for KORU Freedom System in Infusion Clinics

- ✓ 100% of doses successfully administered
- ✓ ~70% of nurses reported ability to multitask, improving workflow efficiency
- ✓ High Nurse (4.8/5) and Patient (4.9/5) Satisfaction

First oncology collaboration ✓

Successful **EU** pilot site study ✓

Successful **US** pilot site study ✓

Current focus

510(k) submission to FDA
Expected 4Q25/1Q26

Anticipated Market Entry
Expected 2H26

1. Third party data & KORU Medical estimates

Oncology Opportunity

97% of Nurses Prefer KORU Freedom System for Subcutaneous Oncology Infusion[1]

Nursing Preference Study: FreedomEdge® vs Manual Syringe Administration

Over 3,000 patients in 6 hospitals received KORU FreedomEdge® infusions from 33 nurses who had previously administered the same >10mL drug via manual push

97% of nurses reported **increased patient interaction** while using the FreedomEdge® Infusion System

81% of nurses experienced **less hand pain** compared to manual syringe administration

91% of nurses found KORU FreedomEdge® Infusion System **easier to use** compared to manual syringe administration

73% of nurses **observed less patient pain** while using FreedomEdge® Infusion System

97% of nurses would recommend the KORU FreedomEdge® Infusion System over manual syringe in subcutaneous oncology infusions, citing ease of use and reduced discomfort as key reasons

1 KORU Medical Nursing Study Data as Presented at PODD on October 28, 2024

Market Opportunity

Key Drivers in the Move from IV to SC Administration

Therapeutic Benefits

30g 5% IVIg Tri-Weekly vs 12g 16% SCIg Weekly



Constant Ig levels with SC vs peaks & valleys in IV→ fewer adverse reactions and infections for patients[1]

Patient Preference



85% of patients choose SC over IV naming less pain, faster infusion, and a less emotionally distressing process as reasons to switch[2]

Cost Savings

Monthly Cost of Administered Specialty Drugs for Privately Insured Individuals



(33-52%) savings when shifting site of care change from hospital to physician offices/home[3]

1. Berger M. Clin Immunol 2004;112:1-7 2. O'Shaughnessy et al Eur J Cancer 2021 3. UnitedHealth Group, Reducing Specialty Drug Costs, 2019

Product Pipeline Opportunity

New Product Launches: Catalysts for SCIg Share Gains and New Market Entries



Flow Controller

Value Proposition

Phase 1 Line extension: Improved COGS and capacity

Phase 2 Next Gen: Improved performance/ accuracy, expanded label indications in new markets

Timing

✓ Phase 1: Launched in Q2 ahead of schedule

Phase 2: 510(k) submission expected 2026

Next Generation Pump

Value Proposition

- Accommodates all available PFS 5mL to 50mL and vial/syringe compatible
- Improved patient mobility, ease of use, and dosing feedback
- Opens new geographic markets

Timing

- 510(k) submission expected 2026



New Consumables Sets

Value Proposition

- Improved patient comfort and convenience
- Customizable platform for new drugs

Timing

- 510(k) submission expected 2H26

Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.

Reconciliation of GAAP Net Loss	**Three Months Ended September 30,**		**Nine Months Ended September 30,**	
to Non-GAAP Adjusted EBITDA:	**2025**	**2024**	**2025**	**2024**
GAAP Net Loss	$ (777,966)	$ (1,580,817)	$ (2,151,070)	$ (4,505,490)
Reorganization Charges	—	396,926	—	496,255
Depreciation and Amortization*	204,482	227,785	631,326	677,019
Interest Income, Net	(74,567)	(112,997)	(226,698)	(364,183)
Tax Expense (Refund)	(150)	—	17,206	—
Stock-based Compensation Expense*	737,398	634,608	1,850,732	1,948,992
Non-GAAP Adjusted EBITDA	$ 89,197	$ (434,495)	$ 121,496	$ (1,747,407)
Weighted average number common shares	46,238,819	45,851,019	46,140,347	45,791,756

Reconciliation of Reported Diluted EPS	**Three Months Ended September 30,**		**Nine Months Ended September 30,**	
to Non-GAAP Adjusted Diluted EPS:	**2025**	**2024**	**2025**	**2024**
Reported Diluted Earnings Per Share	$ (0.02)	$ (0.03)	$ (0.05)	$ (0.10)
Reorganization Charges	—	0.01	—	0.01
Depreciation and Amortization*	—	—	0.01	0.01
Interest Income, Net	—	—	—	(0.01)
Tax Expense (Refund)	—	—	—	—
Stock-based Compensation Expense*	0.02	0.01	0.04	0.04
Non GAAP Adjusted Diluted Earnings Per Share	$ (0.00)	$ (0.01)	$ (0.00)	$ (0.05)

KORU

* Non-cash items